Retrophin Inc., a biopharmaceutical company founded by now-convicted drug executive Martin Shkreli, is rebranding itself as Travere Therapeutics Inc.
The new nameâwhich company officials say is a nod to the Latin roots for truth and pathâsevers another tie to its founder, Mr. Shkreli, who is serving prison time for securities fraud related to his management of two hedge funds and Retrophin. He is scheduled to be released in 2023.
Mr….
WSJ Membership
Customer Service
Tools & Features
Ads
More
Dow Jones Products
Categories